News
23 Oct 2024
Menagen and Pharmosa Announce In-Licensing Collaboration for Sustained-Release Inhaled Treprostinil Product in MENAT Region
Menagen exclusively licenses MENAT rights for inhaled formulation of treprostinil
Menagen exclusively licenses MENAT rights to L606, an inhaled formulation of treprostinil administered twice daily with a short-duration, next-generation nebulizer
Menagens focus is to facilitate localization and access to innovative medicines for patients in need within the MENAT region through a diversified portfolio to cover multiple unmet needs of different illnesses.
Mentioned Companies
Menagen Pharmaceuticals
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance